aTYR PHARMA (ATYR) EBIAT (2019 - 2025)
Historic EBIAT for aTYR PHARMA (ATYR) over the last 6 years, with Q3 2025 value amounting to -$25.7 million.
- aTYR PHARMA's EBIAT fell 4915.71% to -$25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.1 million, marking a year-over-year decrease of 1774.71%. This contributed to the annual value of -$64.0 million for FY2024, which is 2703.73% down from last year.
- According to the latest figures from Q3 2025, aTYR PHARMA's EBIAT is -$25.7 million, which was down 4915.71% from -$19.5 million recorded in Q2 2025.
- Over the past 5 years, aTYR PHARMA's EBIAT peaked at -$7.5 million during Q4 2022, and registered a low of -$25.7 million during Q3 2025.
- In the last 4 years, aTYR PHARMA's EBIAT had a median value of -$14.8 million in 2023 and averaged -$14.8 million.
- Data for aTYR PHARMA's EBIAT shows a peak YoY increase of 1436.77% (in 2023) and a maximum YoY decrease of 9621.16% (in 2023) over the last 5 years.
- aTYR PHARMA's EBIAT (Quarter) stood at -$7.5 million in 2022, then plummeted by 96.21% to -$14.8 million in 2023, then decreased by 1.4% to -$15.0 million in 2024, then tumbled by 72.02% to -$25.7 million in 2025.
- Its EBIAT was -$25.7 million in Q3 2025, compared to -$19.5 million in Q2 2025 and -$14.9 million in Q1 2025.